Verona Pharma Plc ADR [VRNA] stock is trading at $15.46, down -0.32%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VRNA shares have gain 2.79% over the last week, with a monthly amount glided 28.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On August 26, 2022, Piper Sandler initiated with a Overweight rating and assigned a price target of $31 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $25 on September 13, 2021. Jefferies initiated its recommendation with a Buy and recommended $17 as its price target on August 25, 2020. Canaccord Genuity started tracking with a Buy rating for this stock on August 10, 2020, and assigned it a price target of $17. In a note dated April 18, 2019, BTIG Research initiated an Buy rating and provided a target price of $17 on this stock.
Verona Pharma Plc ADR [VRNA] stock has fluctuated between $11.39 and $23.07 over the past year. Currently, Wall Street analysts expect the stock to reach $31.57 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $15.46 at the most recent close of the market. An investor can expect a potential return of 104.2% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.17% with Operating Profit Margin at -75.67%, Pretax Profit Margin comes in at -68.19%, and Net Profit Margin reading is -67.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.25 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.04 points at the first support level, and at 14.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.69, and for the 2nd resistance point, it is at 15.93.
Ratios To Look Out For
For context, Verona Pharma Plc ADR’s Current Ratio is 18.40. Further, the Quick Ratio stands at 18.40, while the Cash Ratio is 17.25.
Transactions by insiders
Recent insider trading involved Rickard Kathleen A., Chief Medical Officer, that happened on May 03 ’24 when 36248.0 shares were sold. Chief Medical Officer, Rickard Kathleen A. completed a deal on Feb 05 ’24 to sell 36248.0 shares. Meanwhile, Director Edwards Martin bought 33736.0 shares on Nov 20 ’23.
